{"commentary":{"count":119,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":64,"youtube":31,"podcast":24},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04039607\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate 9DW","nct_id":"NCT04039607","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-9dw-nct04039607. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CheckMate 9DW","arms":[{"description":null,"label":"Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"description":null,"label":"Sorafenib/lenvatinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-07-09","type":"ACTUAL"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":732,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","type":"DRUG"},{"name":"Ipilimumab","type":"DRUG"},{"name":"Sorafenib","type":"DRUG"},{"name":"lenvatinib","type":"DRUG"}],"last_update":"2026-08-25","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-07-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 4 years"}],"references":[{"citation":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Matilla Pena A, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M. A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). Future Oncol. 2026 Apr;22(10):1135-1152. doi: 10.1080/14796694.2026.2651375. Epub 2026 Apr 14.","pmid":"41981891","type":"DERIVED"},{"citation":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Pena AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M; CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025 May 24;405(10492):1851-1864. doi: 10.1016/S0140-6736(25)00403-9. Epub 2025 May 8.","pmid":"40349714","type":"DERIVED"},{"citation":"Huynh JC, Cho M, Monjazeb A, Al-Obeidi E, Singh A, Tam K, Lara F, Martinez A, Garcia L, Kim EJ. Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma. Invest New Drugs. 2024 Feb;42(1):35-43. doi: 10.1007/s10637-023-01416-w. Epub 2023 Dec 1.","pmid":"38038862","type":"DERIVED"}],"start_date":{"date":"2019-09-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","url":"https://clinicaltrials.gov/study/NCT04039607"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-9dw-nct04039607"}